Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight
Levoketoconazole is expected to emerge as a potential therapy owing to its novelty and oral RoA, thus expected to gain maximum Cushing's Syndrome patient pool.
DelveInsight's 'Cushing's Syndrome Pipeline Insights' report offers a detailed picture of the emerging therapies expected to enter the Cushing's Syndrome market along with detailed coverage of the pipeline therapies under development in pre-clinical as well as clinical stages of development, partnerships taking place in the domain, recent happenings in space and growth prospects across the Cushing's Syndrome domain.
Some of the key highlights of the Cushing's Syndrome Pipeline report:
- Cushing's Syndrome Pipeline report offers a comprehensive analysis of 10+ key players and 10+ key therapies.
- Cushing's Syndrome pipeline comprises Relacorilant (Corcept Therapeutics), Levoketoconazole (Strongbridge Biopharma), CRN-04894 (Crinetics Pharmaceuticals), and several others expected to get launched in the next decade.
- Some of the key companies developing therapies for the treatment of Cushing's Syndrome are Crinetics Pharmaceuticals; Corcept Therapeutics; Strongbridge Biopharma; Orphagen Pharmaceuticals; AstraZeneca; Sparrow Pharmaceuticals; and Cyclacel Pharmaceuticals, among others.
- Out of all the emerging therapies, Levoketoconazole ((Strongbridge Biopharma) is expected to capture the maximum patient pool. Levoketoconazole is a novel oral steroidogenesis inhibitor. It has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing's Syndrome.
- Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors. The drug is currently in phase 3 of the development stage for the treatment of Cushing's Syndrome.
- Roscovitine, or seliciclib, is an oral anticancer agent, acting as an inhibitor of the cyclin-dependent kinases (CDKs) family. The drug is currently in phase 2 of the development stage for the treatment of Cushing's Syndrome.
Request for Sample to know more about the therapies that are set to grab maximum patient pool @ Cushing's Syndrome Emerging Therapies and Forecast
Cushing's Syndrome, also known as hypercortisolism, is a rare hormonal disorder caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol. It mostly affects people of age group aged 20 to 50. The condition can be further divided into two categories, namely, adrenocorticotropic hormone (ACTH)-dependent and ACTH-independent.
Symptoms of Cushing's Syndrome include weight gain, thin arms and legs, a round face, increased fat around the base of the neck, fatty hump between the shoulders, easy bruising, and so on.
For more information on emerging drugs, visit Cushing's Syndrome Pipeline Analysis
Cushing's Syndrome Pipeline Drugs
| Drug | Company | Clinical Phase | MoA | RoA |
| CRN-04894 | Crinetics Pharmaceuticals | Phase I | Melanocortin type 2 receptor antagonists | Oral |
| Relacorilant | Corcept Therapeutics | Phase III | Glucocorticoid receptor antagonists | Oral |
| Levoketoconazole | Strongbridge Biopharma | Preregistration | 14-alpha demethylase inhibitors; Steroid 11-beta-hydroxylase inhibitors | Oral |
| Seliciclib | Cyclacel Pharmaceuticals | Phase II | Cyclin-dependent kinase 9 and 2 inhibitors | Oral |
Request for Sample to know more @ Cushing's Syndrome Pipeline Analysis, Key Companies and Futuristic Trends
Cushing's Syndrome Therapeutic Assessment
The Cushing's syndrome Pipeline report proffers detailed insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.
By Product Type
- Mono
- Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
By Route of Administration
- Intravenous
- Inhalation
- Oral
- Subcutaneous
By Mechanism of Action
- Glucocorticoid receptor antagonists
- 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
- Steroid 11-beta-hydroxylase inhibitors
- Melanocortin type 2 receptor antagonists
- Cyclin-dependent kinase 9 and 2 inhibitors
By Targets
- Melanocortin type 2 receptor
- Multiple Kinase
- 11-beta-hydroxysteroid dehydrogenase type 1
- Glucocorticoid receptor
Get in touch with our Business executive for Informative Business Decisions, Licensing Services and Consulting Solutions
Scope of the Report
Coverage: Global
Key Players: Crinetics Pharmaceuticals; Corcept Therapeutics; Strongbridge Biopharma; Orphagen Pharmaceuticals; AstraZeneca; Sparrow Pharmaceuticals; and Cyclacel Pharmaceuticals among others.
Key Cushing's Syndrome Pipeline Therapies: CRN-04894; Relacorilant; Levoketoconazole; OR 907; AZD 4017; SPI-62; and Seliciclib among others.
Table of Contents
| 1 | Report Introduction |
| 2 | Cushing's Syndrome Overview |
| 3 | Cushing's Syndrome Current Treatment Patterns |
| 4 | Cushing's Syndrome – DelveInsight's Analytical Perspective |
| 5 | Cushing's Syndrome Pipeline Therapeutic Assessment |
| 6 | In-depth Commercial Cushing's Syndrome Pipeline Assessment |
| 7 | Cushing's Syndrome Collaboration Deals |
| 8 | Late Stage Cushing's Syndrome Pipeline Products (Phase III and Preregistration) |
| 9 | Mid-Stage Cushing's Syndrome Pipeline Products (Phase II) |
| 10 | Pre-clinical and Discovery Stage Cushing's Syndrome Pipeline Products |
| 11 | Dormant Cushing's Syndrome Pipeline Products |
| 12 | Inactive Cushing's Syndrome Pipeline Products |
| 13 | Cushing's Syndrome Discontinued Products |
| 14 | Cushing's Syndrome Key Companies |
| 15 | Cushing's Syndrome Key Products |
| 16 | Cushing's Syndrome Dormant and Discontinued Products |
| 17 | Cushing's Syndrome Unmet Needs |
| 18 | Cushing's Syndrome Market Drivers and Barriers |
| 20 | Cushing's Syndrome Future Perspectives and Conclusion |
| 21 | Cushing's Syndrome Pipeline Analyst Views |
| 22 | Appendix |
Visit to know more of what's covered @ Cushing's Syndrome Emerging Therapies
Related Reports
Cushing's Syndrome Market
DelveInsight's "Cushing's Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report.
Endogenous Cushings Syndrome Market
DelveInsight's "Endogenous Cushing's Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report.
Endometriosis Pain Market
DelveInsight's "Endometriosis Pain - Market Insights, Epidemiology, and Market Forecast-2030" report.
Dyslipidemia Market
DelveInsight's "Dyslipidemia - Market Insights, Epidemiology, and Market Forecast-2030" report
Familial Hypercholesterolemia Market Report
DelveInsight's 'Familial Hypercholesterolemia (FH) -Market Insights, Epidemiology and Market Forecast– 2030' report.
Follitropin Alfa Biosimilar Insight
DelveInsight's, "Follitropin alfa– Biosimilar Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Follitropin alfa Biosimilars landscape.
Interferon Biosimilar Insight
DelveInsight's, "Interferon– Biosimilar Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape.
Isocitrate Dehydrogenase Idh Inhibitors Competitive Landscape Market And Pipeline Analysis- 2020
Related Posts
Healthcare Delivery Systems: Kow how the technological revolution has transformed Healthcare Delivery Systems
Hyperkalemia Cocktail: Key companies working in the Hyperkalemia market are Zeria Pharmaceutical/Vifor Pharma and Ardelyx.
Marijuana Clinical Trials: Analysis into key Marijuana Clinical Trials for indications such as Chronic Pain, Epilepsy, Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Huntington's Disease, Irritable Bowel Syndrome, Schizophrenia, Psychosis, Glaucoma, and so many others.
Opiate Withdrawal Cocktail: Several companies are working to tackle Opioid withdrawal symptoms developing novel therapies and repurposing existing ones by making an opiate withdrawal cocktail therapy.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News